Skip to content

Study · Randomized controlled trial · 2016

3 results

Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A

Stroke12 Nov 2015Cited by 97 (Europe PMC)

PMID26564102 (opens in a new tab)PMCIDPMC4689177 (opens in a new tab)DOI10.1161/strokeaha.115.009416 (opens in a new tab)PepBankPUB-26564102
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In stroke patients, Cerebrolysin improved Action Research Arm Test scores versus placebo on day 90.

    In plain wordsIn stroke patients, Cerebrolysin improved arm function test scores more than placebo on day 90.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAction Research Arm Test day 90
    Study

    n: not reported in source

    Comparator
    Placebo (saline)
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    30 mL/d · 21 daysAs given in this study (human).

    Measurements

    Mann-Whitney estimator
    0.71
    day 90
    95% confidence interval
    0.63 to 0.79
    day 90
    p value for Action Research Arm Test score
    < 0.0001
    Action Research Arm Test score on day 90, Cerebrolysin versus placebo

    Source sentences

    Summary
    The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann-Whitney estimator, 0.71; 95% confidence interval, 0.63-0.79; P<0.0001).
    4 context sentences
    Summary · context
    The primary end point was the Action Research Arm Test score on day 90.
    Summary · context
    This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
    Summary · context
    Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.
    Summary · context
    The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In stroke patients, Cerebrolysin improved multivariate global status across 12 outcome scales versus placebo.

    In plain wordsIn stroke patients, Cerebrolysin improved overall status across 12 outcome scales more than placebo.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMultivariate global status
    Study

    n: not reported in source

    Comparator
    Placebo (saline)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL/d · 21 daysAs given in this study (human).

    Measurements

    Mann-Whitney estimator
    0.62
    global status
    95% confidence interval
    0.58 to 0.65
    global status
    p value for multivariate global status
    < 0.0001
    multivariate global status, Cerebrolysin versus placebo

    Source sentences

    Summary
    The multivariate effect size on global status, as assessed using 12 different outcome scales, indicated a small-to-medium superiority of Cerebrolysin (Mann-Whitney estimator, 0.62; 95% confidence interval, 0.58-0.65; P<0.0001).
    3 context sentences
    Summary · context
    This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
    Summary · context
    Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.
    Summary · context
    The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset.
  3. 03HumanRandomized controlled trialSafety outcome

    In stroke patients, Cerebrolysin was well tolerated, with safety comparable to placebo.

    In plain wordsIn stroke patients, Cerebrolysin was well tolerated, with safety comparable to placebo.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeSafety and tolerability
    Study

    n: not reported in source

    Comparator
    Placebo (saline)
    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mL/d · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Cerebrolysin was safe and well tolerated.
    4 context sentences
    Summary · context
    Its safety was comparable with that of the placebo, suggesting a favorable benefit/risk ratio.
    Summary · context
    This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study.
    Summary · context
    Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset.
    Summary · context
    The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04751136

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

Mansoura University Children Hospitaln = 6430 Sept 2016 to 30 Aug 2019

Down Syndrome

Trial pageClinicalTrials.govUpdated 11 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.